BeiGene is a life sciences biotechnology company.
BeiGene, founded in October, 2010 and headquartered in Beijing, is an anti-tumor drug developer. The founder is Wu Xiaobin. Listed on the HKEX on August 8, 2018, the company's major shareholders are Beigene, Ltd.. Rivals that have direct and indirect competition with BeiGene include Kintor, HitGen, Aprea Therapeutics, BridgeBio Pharma, etc.
Singaporean Prime Minister Lee Hsien Loong meets with weifenghe
Luoxin pharmaceutical: fosapitam for injection and meglumine have obtained the drug registration certificate
Baiji Shenzhou PD-1 monoclonal antibody baizean ® The ninth indication was obtained and the first-line treatment for nasopharyngeal carcinoma was approved
A new breakthrough in the first-line treatment of advanced esophageal cancer: PD-1 monoclonal antibody baizean ® Global phase 3 clinical trials reached the primary end point
2022 China AI Health 30 Report
ResearchConsumer Staples, Healthcare, Technology
WIA2020 | Rising Tech Stars 2020: Global & China's 100
Boeing's revenue in the first quarter was $14 billion, with a market estimate of $15.94 billion.
Tesla unveiled a new giant 360mwh Megapack energy storage project
Baiji China: the tentative list is a normal step and will not affect the listing of the company on NASDAQ
Ministry of agriculture and rural areas: implement the ten-year fishing ban on the Yangtze River in 2022 and promote the conservation of aquatic biological resources
The communication service sector opened stronger
Hillhouse Q4 position: increased holdings of ideal automobile and Xiaopeng automobile sea, and ideal automobile rushed into the top ten
The Italian Ministry of economy said it expected GDP to grow by more than 4% in 2022.
Hong Kong Pharmaceutical stocks generally rose, with Cinda biology up nearly 6%
Yu Minhong responded to New Oriental's business reduction, dismissal and other issues: about 50000 employees remained
Zhejiang Jiaxing further liberalizes settlement conditions
54% off! Pamipali, the first PARP inhibitor approved for the treatment of platinum sensitive and platinum resistant recurrent ovarian cancer, was included in Medicare